{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"164.1","value":"510.2"},{"groupId":"OG001","spread":"232.2","value":"434.1"},{"groupId":"OG002","spread":"402.6","value":"535.8"},{"groupId":"OG003","spread":"140.9","value":"457.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.6","value":"445.8"},{"groupId":"OG001","spread":"215.3","value":"418.7"},{"groupId":"OG002","spread":"496.9","value":"585.6"},{"groupId":"OG003","spread":"131.7","value":"442.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"122.6","value":"403.7"},{"groupId":"OG001","spread":"103.9","value":"413.9"},{"groupId":"OG002","spread":"168.6","value":"507.1"},{"groupId":"OG003","spread":"125.8","value":"400.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"103.9","value":"509.3"},{"groupId":"OG001","spread":"129.3","value":"554.3"},{"groupId":"OG002","spread":"234.0","value":"590.3"},{"groupId":"OG003","spread":"251.3","value":"486.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"109.4","value":"412.5"},{"comment":"NA indicates that the SD was not estimable for 1 participant.","groupId":"OG001","spread":"NA","value":"483.0"},{"comment":"NA indicates that the SD was not estimable for 1 participant.","groupId":"OG002","spread":"NA","value":"152.0"},{"groupId":"OG003","spread":"169.0","value":"443.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Cycle 10"},{"categories":[{"measurements":[{"comment":"NA indicates that the SD was not estimable for 1 participant.","groupId":"OG000","spread":"NA","value":"352.0"},{"comment":"NA indicates that the SD was not estimable for 1 participant.","groupId":"OG001","spread":"NA","value":"265.0"},{"comment":"NA indicates that the SD was not estimable for 1 participant.","groupId":"OG003","spread":"NA","value":"567.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Cycle 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"Blood samples were collected at specified timepoints for the assessment of Ceoi of pegenzileukin.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with previously untreated Stage IV NSCLC and PD-L1 TPS of \\>=50% were included in this cohort. Participants received pegenzileukin 24 μg/kg along with pembrolizumab 200 mg via IV infusion over 30 minutes q3w on Day 1 of each cycle (each cycle is 21 days) (as 1L therapy), until PD, unacceptable AE or other full permanent discontinuation criteria was met or completion of Cycle 35.","id":"OG000","title":"Cohort A1:NSCLC, PD-L1 TPS >=50%:Pegenzileukin 24 μg/kg + Pembrolizumab as 1L Therapy"},{"description":"Participants with previously untreated Stage IV NSCLC and PD-L1 TPS of 1%-49% were included in this cohort. Participants received pegenzileukin 24 μg/kg along with pembrolizumab 200 mg via IV infusion over 30 minutes q3w on Day 1 of each cycle (each cycle is 21 days) (as 1L therapy), until PD, unacceptable AE or other full permanent discontinuation criteria was met or completion of Cycle 35.","id":"OG001","title":"Cohort A2:NSCLC, PD-L1 TPS 1%-49%:Pegenzileukin 24 μg/kg+Pembrolizumab as 1L Therapy"},{"description":"Participants with NSCLC for whom SOC was not in their best interest or where no SOC was established were included in this cohort. Participants received pegenzileukin 24 μg/kg along with pembrolizumab 200 mg via IV infusion over 30 minutes q3w on Day 1 of each cycle (each cycle is 21 days) (as 2/3L therapy), until PD, unacceptable AE or other full permanent discontinuation criteria was met or completion of Cycle 35.","id":"OG002","title":"Cohort B1: NSCLC:Pegenzileukin 24 μg/kg+Pembrolizumab as 2/3L Therapy"},{"description":"Participants with mesothelioma who had no SOC established and had experienced PD during or after at least one but no more than 2 prior regimens were included in this cohort. Participants received pegenzileukin 24 μg/kg along with pembrolizumab 200 mg via IV infusion over 30 minutes q3w on Day 1 of each cycle (each cycle is 21 days) (as 2/3L therapy), until PD, unacceptable AE or other full permanent discontinuation criteria was met or completion of Cycle 35.","id":"OG003","title":"Cohort C1:Mesothelioma:Pegenzileukin 24 μg /kg+Pembrolizumab as 2/3L Therapy"}],"paramType":"MEAN","populationDescription":"The PK population consisted of all participants from exposed population with at least 1 PK concentration available after the first dose of study treatment. Only participants with data collected at specified timepoints are reported. Eventually, the participants discontinued as they progressed in the study. Hence, fewer participants at each cycle and no participants returned on Cycle 15 in Cohort B1 Arm.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 2, 4, 7, 10, and 15 (each cycle is 21 days)","title":"All Cohorts: Concentration at End of Infusion (Ceoi) of Pegenzileukin","type":"SECONDARY","unitOfMeasure":"ng/mL"}